Clinical strategies have been implemented to counteract cardiovascular risk factors in breast cancer survivors including modifications in treatments, monitoring of symptoms, and pharmacological strategies (i.e., beta-blockers, angiotensin-converting enzyme (ACE)-inhibitors, etc.)[34]. This evidence concerns the gene ACE and breast cancer.